866-997-4948(US-Canada Toll Free)

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 144 Pages

Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Review, H2 2016, provides in depth analysis on Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Overview 8
Therapeutics Development 9
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Stage of Development 9
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Therapy Area 10
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Indication 11
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Companies 15
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Products under Development by Universities/Institutes 23
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Therapeutics Assessment 25
Assessment by Monotherapy/Combination Products 25
Assessment by Mechanism of Action 26
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Companies Involved in Therapeutics Development 30
AbbVie Inc 30
ACEA Biosciences, Inc. 32
Advinus Therapeutics Ltd 33
ArQule, Inc. 34
BeiGene, Ltd. 35
Beijing Hanmi Pharmaceutical Co Ltd 36
Biogen Inc 37
Bristol-Myers Squibb Company 38
Celgene Corporation 39
CrystalGenomics, Inc. 40
Genentech, Inc. 41
Hanmi Pharmaceuticals, Co. Ltd. 42
LSK BioPartners, Inc. 43
Merck KGaA 44
Ono Pharmaceutical Co., Ltd. 45
Pharmacyclics, Inc. 46
Principia Biopharma Inc. 47
Redx Pharma Plc 48
Simcere Pharmaceutical Group 49
Sunesis Pharmaceuticals, Inc. 50
Takeda Pharmaceutical Company Limited 51
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Drug Profiles 52
ABBV-599 - Drug Profile 52
AC-058 - Drug Profile 53
acalabrutinib - Drug Profile 54
Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia - Drug Profile 57
ARQ-531 - Drug Profile 58
BGB-3111 - Drug Profile 59
BIIB-068 - Drug Profile 62
BMS-986142 - Drug Profile 63
BMS-986195 - Drug Profile 64
CG-026806 - Drug Profile 65
CG-036806 - Drug Profile 66
Drug to Inhibit BTK for Undisclosed Indications - Drug Profile 67
DTRMWXHS-12 - Drug Profile 68
EBI-1266 - Drug Profile 69
EBI-1367 - Drug Profile 70
HCI-1401 - Drug Profile 71
HCI-1684 - Drug Profile 72
HM-71224 - Drug Profile 73
ibrutinib - Drug Profile 74
M-2951 - Drug Profile 97
M-7583 - Drug Profile 98
ONO-4059 - Drug Profile 99
PLS-123 - Drug Profile 101
PNQ-154 - Drug Profile 102
PNQ-849 - Drug Profile 103
PRN-1008 - Drug Profile 104
PRN-473 - Drug Profile 106
RDX-002 - Drug Profile 107
RG-7845 - Drug Profile 108
Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis - Drug Profile 109
Small Molecule to Inhibit BTK and IRAK4 for Autoimmune Disorders and Rheumatoid Arthritis - Drug Profile 110
Small Molecule to Inhibit BTK for Immunology - Drug Profile 111
Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer - Drug Profile 112
Small Molecule to Inhibit BTK for Oncology - Drug Profile 113
Small Molecule to Target BTK for Immunology - Drug Profile 114
Small Molecules to Inhibit BTK for Oncology - Drug Profile 115
Small Molecules to Inhibit BTK for Rheumatoid Arthritis - Drug Profile 116
SNS-062 - Drug Profile 118
spebrutinib besylate - Drug Profile 120
TAK-020 - Drug Profile 122
X-022 - Drug Profile 123
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Dormant Projects 124
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Discontinued Products 127
Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) - Featured News & Press Releases 128
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 140
Contact Us 140
Disclaimer 141

List of Tables
Number of Products under Development for, H2 2016 12
Number of Products under Development by Therapy Area, H2 2016 13
Number of Products under Development by Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Development by Companies, H2 2016 (Contd..2) 21
Products under Development by Companies, H2 2016 (Contd..3) 22
Products under Development by Companies, H2 2016 (Contd..4) 23
Products under Development by Companies, H2 2016 (Contd..5) 24
Products under Development by Companies, H2 2016 (Contd..6) 25
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Products under Investigation by Universities/Institutes, H2 2016 27
Assessment by Monotherapy/Combination Products, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 29
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Pipeline by AbbVie Inc, H2 2016 34
Pipeline by ACEA Biosciences, Inc., H2 2016 35
Pipeline by Advinus Therapeutics Ltd, H2 2016 36
Pipeline by ArQule, Inc., H2 2016 37
Pipeline by BeiGene, Ltd., H2 2016 38
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2016 39
Pipeline by Biogen Inc, H2 2016 40
Pipeline by Bristol-Myers Squibb Company, H2 2016 41
Pipeline by Celgene Corporation, H2 2016 42
Pipeline by CrystalGenomics, Inc., H2 2016 43
Pipeline by Genentech, Inc., H2 2016 44
Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 45
Pipeline by LSK BioPartners, Inc., H2 2016 46
Pipeline by Merck KGaA, H2 2016 47
Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 48
Pipeline by Pharmacyclics, Inc., H2 2016 49
Pipeline by Principia Biopharma Inc., H2 2016 50
Pipeline by Redx Pharma Plc, H2 2016 51
Pipeline by Simcere Pharmaceutical Group, H2 2016 52
Pipeline by Sunesis Pharmaceuticals, Inc., H2 2016 53
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 54
Dormant Projects, H2 2016 127
Dormant Projects (Contd..1), H2 2016 128
Dormant Projects (Contd..2), H2 2016 129
Discontinued Products, H2 2016 130

List of Figures
Number of Products under Development for, H2 2016 12
Number of Products under Development by Therapy Area, H2 2016 13
Number of Products under Development by Top 10 Indication, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 28
Number of Products by Stage and Mechanism of Actions, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 30
Number of Products by Molecule Types, H2 2016 31
Number of Products by Stage and Molecule Type, H2 2016 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *